Selecting Combination Versus Monotherapy in EGFR Mutated Metastatic Non-Small Cell Lung Cancer

In this segment, Dr. Devarakonda asks Dr. Rotow to outline the advantages and limitations of combination regimens compared with single agent EGFR tyrosine kinase inhibitors in the first line treatment of EGFR mutated metastatic non-small cell lung cancer. Dr. Rotow discusses how combination approaches have demonstrated overall survival benefit, supporting their use for many patients, particularly those with higher risk features such as brain metastases or greater disease burden.

At the same time, she highlights that monotherapy remains an appropriate option for selected patients, including those with significant comorbidities, borderline performance status, or strong preferences for less intensive therapy. The panel emphasizes that while combination therapy is increasingly viewed as a default for many patients, careful assessment of clinical risk factors, tolerability, and patient goals remains essential. This discussion reinforces that treatment selection in EGFR mutated metastatic non-small cell lung cancer must balance survival benefit with toxicity, logistics, and individualized patient priorities.